Wealth Enhancement Advisory Services LLC Buys 498 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Wealth Enhancement Advisory Services LLC boosted its stake in shares of Exact Sciences Co. (NASDAQ:EXAS) by 1.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,809 shares of the medical research company’s stock after buying an additional 498 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Exact Sciences were worth $2,473,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in EXAS. Asahi Life Asset Management CO. LTD. increased its holdings in shares of Exact Sciences by 4.2% during the fourth quarter. Asahi Life Asset Management CO. LTD. now owns 4,390 shares of the medical research company’s stock valued at $325,000 after acquiring an additional 175 shares in the last quarter. National Bank of Canada FI increased its stake in Exact Sciences by 30.9% during the 4th quarter. National Bank of Canada FI now owns 848 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 200 shares in the last quarter. Sanders Morris Harris LLC raised its holdings in Exact Sciences by 4.2% in the first quarter. Sanders Morris Harris LLC now owns 5,000 shares of the medical research company’s stock worth $345,000 after buying an additional 200 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Exact Sciences by 0.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 37,200 shares of the medical research company’s stock worth $2,752,000 after buying an additional 205 shares in the last quarter. Finally, Wahed Invest LLC grew its holdings in shares of Exact Sciences by 8.0% during the fourth quarter. Wahed Invest LLC now owns 3,047 shares of the medical research company’s stock valued at $225,000 after buying an additional 227 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Kevin T. Conroy sold 1,155 shares of the stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $60.15, for a total value of $69,473.25. Following the completion of the sale, the chief executive officer now directly owns 1,156,191 shares of the company’s stock, valued at $69,544,888.65. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders have sold 1,498 shares of company stock worth $90,105. Company insiders own 1.36% of the company’s stock.

Exact Sciences Trading Up 0.0 %

Shares of EXAS stock opened at $43.19 on Thursday. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $100.77. The firm has a fifty day moving average price of $49.20 and a 200-day moving average price of $59.70. The company has a market cap of $7.97 billion, a price-to-earnings ratio of -32.72 and a beta of 1.22. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.64 and a quick ratio of 1.45.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Wednesday, May 8th. The medical research company reported ($0.50) EPS for the quarter, hitting analysts’ consensus estimates of ($0.50). Exact Sciences had a negative return on equity of 7.12% and a negative net margin of 9.48%. The business had revenue of $637.52 million during the quarter, compared to analysts’ expectations of $624.95 million. As a group, equities analysts predict that Exact Sciences Co. will post -1.15 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Jefferies Financial Group began coverage on Exact Sciences in a research report on Monday, June 3rd. They issued a “buy” rating and a $75.00 price objective on the stock. Scotiabank began coverage on Exact Sciences in a report on Thursday, June 27th. They set a “sector outperform” rating and a $70.00 price target on the stock. Canaccord Genuity Group dropped their price objective on Exact Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, May 9th. BTIG Research decreased their target price on Exact Sciences from $80.00 to $70.00 and set a “buy” rating for the company in a research report on Wednesday, June 26th. Finally, Citigroup dropped their price target on shares of Exact Sciences from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Two investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat.com, Exact Sciences has a consensus rating of “Moderate Buy” and an average price target of $86.80.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.